Global Mild Cognitive Impairment Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Mild Cognitive Impairment treatment during 2019. Clinical development activities are being undertaken by more than 20 companies including AbbVie Inc, Addex Therapeutics Ltd, AgeneBio Inc, Avraham Pharmaceuticals Ltd, Biogen Inc and others.
A Significant contribution to the Mild Cognitive Impairment pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Mild Cognitive Impairment pipeline included 21 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Mild Cognitive Impairment condition and increased access to investments is encouraging growth of Mild Cognitive Impairment drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Mild Cognitive Impairment drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Mild Cognitive Impairment therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Mild Cognitive Impairment pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Mild Cognitive Impairment. Further, orphan drug status, fast track designation, grants awarded and other special status for Mild Cognitive Impairment pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Mild Cognitive Impairment pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Mild Cognitive Impairment Pipeline candidates-
A Significant contribution to the Mild Cognitive Impairment pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Mild Cognitive Impairment pipeline included 21 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Mild Cognitive Impairment condition and increased access to investments is encouraging growth of Mild Cognitive Impairment drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Mild Cognitive Impairment drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Mild Cognitive Impairment therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Mild Cognitive Impairment pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Mild Cognitive Impairment. Further, orphan drug status, fast track designation, grants awarded and other special status for Mild Cognitive Impairment pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Mild Cognitive Impairment pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Mild Cognitive Impairment Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Mild Cognitive Impairment drugs
- Late phase: Phase 3 and in-approval Mild Cognitive Impairment drugs
- Company overview
- Snapshot
- Mild Cognitive Impairment therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Mild Cognitive Impairment- Disease Overview
2.2 Mild Cognitive Impairment- Pipeline Snapshot
2.3 Mild Cognitive Impairment- Pipeline Drugs by Phase
2.4 Mild Cognitive Impairment- Pipeline Drugs by Company
2.5 Mild Cognitive Impairment- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 AbbVie Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.2 Addex Therapeutics Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.3 AgeneBio Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.4 Avraham Pharmaceuticals Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.5 Biogen Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.6 CereSpir Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.7 CuraSen Therapeutics Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.8 Eisai Co Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.9 Eli Lilly and Co Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.10 Fujifilm Toyama Chemical Co Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.11 IntelGenx Corp Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.12 Merck & Co Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.13 Neuron Biopharma SA Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.14 NLS Pharma Group Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.15 Octapharma AG Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.16 Partner Therapeutics Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.17 Pfizer Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.18 ProNeurogen Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.19 Protekt Therapeutics Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.20 SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.21 Therapix Biosciences Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Mild Cognitive Impairment- Phase 1 Drug Details
4.2 Mild Cognitive Impairment- Phase 1 Drug Overview
4.3 Mild Cognitive Impairment- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Mild Cognitive Impairment- Phase 2 Drug Details
5.2 Mild Cognitive Impairment- Phase 2 Drug Overview
5.3 Mild Cognitive Impairment- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Mild Cognitive Impairment- Phase 3 Drug Details
6.2 Mild Cognitive Impairment- Phase 3 Drug Overview
6.3 Mild Cognitive Impairment- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Mild Cognitive Impairment- Pre-clinical Phase Drug Details
7.2 Mild Cognitive Impairment- Pre-clinical Phase Drug Overview
7.3 Mild Cognitive Impairment- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Mild Cognitive Impairment- Disease Overview
2.2 Mild Cognitive Impairment- Pipeline Snapshot
2.3 Mild Cognitive Impairment- Pipeline Drugs by Phase
2.4 Mild Cognitive Impairment- Pipeline Drugs by Company
2.5 Mild Cognitive Impairment- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 AbbVie Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.2 Addex Therapeutics Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.3 AgeneBio Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.4 Avraham Pharmaceuticals Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.5 Biogen Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.6 CereSpir Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.7 CuraSen Therapeutics Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.8 Eisai Co Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.9 Eli Lilly and Co Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.10 Fujifilm Toyama Chemical Co Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.11 IntelGenx Corp Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.12 Merck & Co Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.13 Neuron Biopharma SA Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.14 NLS Pharma Group Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.15 Octapharma AG Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.16 Partner Therapeutics Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.17 Pfizer Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.18 ProNeurogen Inc Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.19 Protekt Therapeutics Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.20 SBI Pharmaceuticals Co Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
3.21 Therapix Biosciences Ltd Mild Cognitive Impairment Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Mild Cognitive Impairment- Phase 1 Drug Details
4.2 Mild Cognitive Impairment- Phase 1 Drug Overview
4.3 Mild Cognitive Impairment- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Mild Cognitive Impairment- Phase 2 Drug Details
5.2 Mild Cognitive Impairment- Phase 2 Drug Overview
5.3 Mild Cognitive Impairment- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Mild Cognitive Impairment- Phase 3 Drug Details
6.2 Mild Cognitive Impairment- Phase 3 Drug Overview
6.3 Mild Cognitive Impairment- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Mild Cognitive Impairment- Pre-clinical Phase Drug Details
7.2 Mild Cognitive Impairment- Pre-clinical Phase Drug Overview
7.3 Mild Cognitive Impairment- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
